Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Olatunji Alese

Hematology & Oncology Atlanta, GA Medical Doctor

NPI 1053631010 CMS profile 1247162

1365 Clifton Rd Ne, Winship Cancer Institute, Atlanta, GA 30322

Open in the dashboard

General payments

$136,996

158 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$15,318,840 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Olatunji Alese of Atlanta, GA is reported in the CMS Open Payments database as having received $136,996 across 158 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $15,318,840 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,473 23
2024 General $52,831 68
2023 General $31,901 41
2022 General $14,611 12
2021 General $7,500 1
2020 General $9,250 2
2019 General $5,430 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Olatunji Alese
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Olatunji Alese were reported at $15,473. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Olatunji Alese Hematology & Oncology median Middle half National median
2019 $5,430 $529 $121–$2,516 $163
2020 $9,250 $339 $82–$2,213 $114
2021 $7,500 $263 $49–$1,965 $132
2022 $14,611 $416 $103–$2,395 $149
2023 $31,901 $542 $125–$2,646 $160
2024 $52,831 $692 $141–$3,008 $164
2025 $15,473 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $24,466 28 payments
  2. Taiho Oncology, Inc. $23,663 7 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $23,306 12 payments
  4. Exelixis Inc. $15,470 42 payments
  5. Ipsen Biopharmaceuticals, Inc $9,298 9 payments
  6. Incyte Corporation $7,281 9 payments
  7. AbbVie, Inc. $5,538 3 payments
  8. Array BioPharma Inc. $5,520 2 payments
  9. Eli Lilly and Company $5,077 13 payments
  10. Aadi Bioscience, Inc. $3,415 7 payments
  11. Other $13,962 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $92,856 27 payments
  2. Travel and Lodging $16,362 54 payments
  3. Honoraria $12,525 5 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $11,389 13 payments
  5. Food and Beverage $3,802 58 payments
  6. Education $61 1 payment
Products named General payments · program years 2019–2025
  1. Lonsurf $23,663 7 payments
  2. FRUZAQLA $23,306 12 payments
  3. ONIVYDE $9,248 8 payments
  4. INQOVI $7,500 1 payment
  5. CABOMETYX Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) $6,162 15 payments
  6. BRAFTOVI $5,650 3 payments
  7. CABOMETYX Oncology $4,252 16 payments
  8. FYARRO $3,415 7 payments
  9. JEMPERLI $3,200 2 payments
  10. IMFINZI $2,479 2 payments
  11. Other $3,031 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

176

Median for Hematology-Oncology: 604

Drug cost

$296,054

Median for Hematology-Oncology: $1,306,514

Branded share of claims

22.2%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lonsurf Trifluridine/Tipiracil Hcl Brand 17 $117,141
Lanreotide Acetate Generic 12 $98,911
Creon Lipase/Protease/Amylase Brand 22 $69,048
Imatinib Mesylate Generic 20 $9,371
Ondansetron Hcl Generic 24 $821
Prochlorperazine Maleate Generic 27 $251
Dexamethasone Generic 15 $244
Oxycodone Hcl Generic 21 $141
Pantoprazole Sodium Generic 18 $127

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$13,389

Medicare's payments for the services billed

Medicare patients

84

Average age 74

Services billed

191

41 women, 43 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Cancer 62%
Diabetes 37%
Arthritis 37%
Chronic kidney disease 26%
Ischemic heart disease 23%
Atrial fibrillation 20%
Osteoporosis 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FRUZAQLA
  • Takeda Pharmaceuticals U.S.A., Inc. $10,638
$10,638 — —
CABOMETYX
  • Exelixis Inc. $6,162
$6,162 — —
ONIVYDE
  • Ipsen Biopharmaceuticals, Inc $5,487
$5,487 — —
Lonsurf
  • Taiho Oncology, Inc. $2,458
$2,458 17 —
JEMPERLI
  • GlaxoSmithKline, LLC. $1,600
$1,600 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

158 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record